ASH Expert Roundtable: Follicular Lymphoma

Latest ASH Expert Roundtable: Follicular Lymphoma News

Pirtobrutinib Shows Potential in Heavily Pretreated Follicular Lymphoma

Treatment with single-agent pirtobrutinib (Jaypirca), a non-covalent Bruton's tyrosine kinase (BTK) inhibitor,

Derick Alison Derick Alison

Liso-Cel a Potential New CAR-T Option for High-Risk R/R Follicular Lymphoma

Patients with high-risk relapsed/refractory follicular lymphoma experienced statistically significant and clinically meaningful

Derick Alison Derick Alison

Tisa-Cel Yields Durable Responses in R/R Follicular Lymphoma

Patients with relapsed/refractory follicular lymphoma experience durable responses when treated with tisagenlecleucel

Derick Alison Derick Alison

Responses to Mosunetuzumab in Follicular Lymphoma Remain Durable at 3 Years

Mosunetuzumab (Lunsumio) is a first-in-class bispecific antibody that last year received accelerated

Derick Alison Derick Alison
adbanner